Myclausen (mycophenolate mofetil)
Generic
- Region
- 🇪🇺 EU
- Active substance
- mycophenolate mofetil
- Company
- Passauer Pharma GmbH
- Status
- Authorised
- Therapeutic area
- Graft Rejection
- EU approval
- Thu 07 Oct 2010
- Designations
- Generic
- Application
- EMEA/H/C/001218
- ATC
- L04AA06
- Official record
- www.ema.europa.eu
Indication
Myclausen is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 CellCept Authorised · Roche Registration GmbH
- 🇪🇺 Myfenax Authorised · Teva B.V.
- 🇪🇺 Mycophenolate mofetil Teva Authorised · Teva Pharma B.V.
Follow Myclausen
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.